Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model

被引:74
作者
Firsov, Alexander A.
Smirnova, Maria V.
Lubenko, Irene Yu.
Vostrov, Sergey N.
Portnoy, Yury A.
Zinner, Stephen H.
机构
[1] Russian Acad Med Sci, Gause Inst New Antibiot, Dept Pharmacokinet & Pharmacodynam, Moscow 119021, Russia
[2] Harvard Univ, Sch Med, Mt Auburn Hosp, Cambridge, MA 02138 USA
关键词
S; aureus; pharmacodynamics; resistance; in vitro model;
D O I
10.1093/jac/dkl387
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: To extend the mutant selection window (MSW) hypothesis to include antibiotics in addition to fluoroquinolones, the pharmacodynamics of daptomycin (DAP) and vancomycin (VAN) and their ability to prevent the selection of resistant Staphylococcus aureus were studied in an in vitro model that simulates antibiotic concentrations below the MIC, between the MIC and the mutant prevention concentration (MPC), and above the MPC. Methods: Two clinical isolates of S. aureus, S. aureus 866 (MICDAP 0.35, MICVAN 0.7, MPCDAP 1.1, MPCVAN 2.4 mg/L) and S. aureus 10 (MICDAP 1.1, MICVAN 1.3, MPCDAP 5.5, MPCVAN 11 mg/L), were exposed for five consecutive days to once-daily daptomycin (half-life 9 h) and twice-daily vancomycin (half-life 6 h) at the ratio of 24 h area under the concentration-time curve (AUC(24)) to MIC that varied over a 16- to 30-fold range. The cumulative antimicrobial effect was expressed by its intensity (I-E). Changes in susceptibility and numbers of surviving organisms on agar plates containing 2x and 4x MIC of daptomycin or vancomycin were monitored daily. Results: The I-E-log AUC(24)/MIC plots were bacterial strain- and antibiotic-independent. This allowed combination of data obtained with both antibiotics and both organisms. Based on the sigmoid relationship between I-E and the AUC(24)/MIC (r(2) = 0.9), the antistaphylococcal effect of the therapeutic doses of daptomycin (4 and 6 mg/kg) against a hypothetical S. aureus with MIC equal to the MIC90 (AUC(24)/MIC90 380 and 570 h, respectively) was predicted to be similar to the effect of two 1 g doses of vancomycin given at a 12 h interval (AUC(24)/MIC90 200 h). AUC(24)/MIC relationships of the final-to-initial MIC ratio and logarithm of the ratio of maximal-to-initial numbers of organisms resistant to 2x and 4x MIC of daptomycin or vancomycin were bell-shaped and bacterial strain- and antibiotic-independent. Based on these relationships, an AUC(24)/MIC ratio that protects against the selection of resistant mutants was predicted at >= 200 h. This protective value is less than the AUC(24)/MIC(90)s provided by the 4 mg/kg dose and considerably less than the 6 mg/kg dose of daptomycin, but it is close to the AUC(24)/MIC90 provided by two 1 g doses of vancomycin. Conclusions: These findings support the MSW hypothesis and suggest comparable antistaphylococcal effects of clinically achievable AUC(24)/MIC(90)s of daptomycin and vancomycin but slightly better prevention against the selection of resistant S. aureus by daptomycin.
引用
收藏
页码:1185 / 1192
页数:8
相关论文
共 32 条
[1]   VANCOMYCIN SERUM-PROTEIN BINDING DETERMINATION BY ULTRAFILTRATION [J].
ACKERMAN, BH ;
TAYLOR, EH ;
OLSEN, KM ;
ABDELMALAK, W ;
PAPPAS, AA .
DRUG INTELLIGENCE & CLINICAL PHARMACY, 1988, 22 (04) :300-303
[2]   In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model [J].
Akins, RL ;
Rybak, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (07) :1925-1929
[3]   Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations [J].
Akins, RL ;
Rybak, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (02) :454-459
[4]   Evolution of ciprofloxacin-resistant Staphylococcus aureus in in vitro pharmacokinetic environments [J].
Campion, JJ ;
McNamara, PJ ;
Evans, ME .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (12) :4733-4744
[5]   Pharmacodynamic modeling of the evolution of levofloxacin resistance in Staphylococcus aureus [J].
Campion, JJ ;
Chung, P ;
McNamara, PJ ;
Titlow, WB ;
Evans, ME .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (06) :2189-2199
[6]   Daptomycin dose-effect relationship against resistant gram-positive organisms [J].
Cha, R ;
Grucz, RG ;
Rybak, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (05) :1598-1603
[7]   Influence of protein binding under controlled conditions on the bactericidal activity of daptomycin in an in vitro pharmacodynamic model [J].
Cha, R ;
Rybak, MJ .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 54 (01) :259-262
[8]   Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects [J].
Dvorchik, BH ;
Brazier, D ;
DeBruin, MF ;
Arbeit, RD .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (04) :1318-1323
[9]   Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: Action of ciprofloxacin against Escherichia coli in an in vitro dynamic model [J].
Firsov, AA ;
Vostrov, SN ;
Shevchenko, AA ;
Cornaglia, G .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (06) :1281-1287
[10]   Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: New insight into a widely used concept [J].
Firsov, AA ;
Shevchenko, AA ;
Vostrov, SN ;
Zinner, SH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (03) :659-665